Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Packerfan666on Feb 06, 2020 10:53am

60 Views

Post# 30651754

RE:RE:CEO VERY CONFIDENT

Sloomoo or Jack whoever you are. I asked you to keep my name out of your mouth. You don't know me. I talked to him after any PR. That's not the point though, I tried to tell you all a couple of concerns , I got shot down out your ingnorance, it's over now, so stop talking about me. You only use my name to fit your tired narrative. The fact is , I know more about this company than you ever could, I have more emails, phone records and deep dive digging than you could. I don't mind you saying you don't believe me, we can agree to disagree but I have 350,000 invested. Don't think you know more, that's just ignorant.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity